Vancouver, British Columbia--(Newsfile Corp. - March 3, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announced that it has retained Lucosky Brookman LLP, a distinguished corporate finance and securities law firm, to assist in evaluating an uplisting to a senior national securities exchange such as the Nasdaq Capital Market or the New York Stock Exchange (NYSE).
Lucosky Brookman is the industry leader in "Uplisting" domestic or foreign quoted OTC companies and foreign exchange listed companies to the NASDAQ or NYSE. The firm brings extensive experience in corporate finance, mergers and acquisitions, and securities law, advising both private and public companies on listing applications, regulatory compliance, and corporate governance matters.
"A strong corporate foundation and exposure to a wider investor base will become increasingly more important as we advance towards a clinical trial for our lead G-CSF antibody candidate and pursue the rapid advancement of our mRNA drug discovery program. Exploring an uplisting to a senior exchange is a natural step in our evolution, and we are confident that partnering with Lucosky Brookman will help us move forward strategically. A listing on a major exchange would enhance our visibility, strengthen investor confidence, and support long-term growth," said Salim Dhanji, PhD, Chief Executive Officer of ME Therapeutics.
ME Therapeutics plans to assess the necessary steps for uplisting and will work to meet the financial and regulatory requirements for approval. However, there is no guarantee that the Company will satisfy the criteria, that an application will be accepted or as to the timing for completion of any of these steps.
Myeloid Enhancement (ME) Therapeutics is a preclinical stage, Vancouver based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. For more information, please visit http://www.metherapeutics.com and the Company's profile on SEDAR+ at http://www.sedarplus.ca.
ON BEHALF OF THE BOARD
"Salim Dhanji"
Dr. Salim Dhanji
Chief Executive Officer and Director
For further information, please contact:
Dr. Salim Dhanji
Telephone: (236) 516-7714
Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding the Company's plans to pursue a listing on a senior national securities exchange in the United States such as Nasdaq Capital Market or the NYSE, that the Company will work towards meeting the financial and regulatory requirements for approval of such a listing, statements regarding the Company's research plans, the intended outcomes of the research, the intended benefits and applications of the Company's technology, and the Company's plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the application for uplisting to a senior exchange may not be completed, or that if completed may not to be accepted in a timely manner or at all, that the Company incurs costs in pursuit of a listing that is not completed, that the Company's research does not progress as expected or does not have favorable results, that the Company's business may not develop as set out in this news release and the various other risks set out in the Company's public disclosure record. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243022
SOURCE: ME Therapeutics Holdings Inc.
